Contact
searchSearch
HMP Global
Quiz

Trivia: Psoriasis Treatment Perspectives and Expectations

Jessica Garlewicz
05/18/2022

Related Content

Baldwin
Videos
The Skin Microbiome: Dermatologic Insights
05/22/2026
Hilary E. Baldwin, MD; Riya Gandhi, MA
Dr Hilary Baldwin discusses how evolving insights into the skin microbiome are reshaping the understanding of acne, eczema, rosacea, and other inflammatory skin diseases.
Dr Hilary Baldwin discusses how evolving insights into the skin microbiome are reshaping the understanding of acne, eczema, rosacea, and other inflammatory skin diseases.
Dr Hilary Baldwin discusses how...
05/22/2026
The Dermatologist
Masterclasses in Dermatology Saturday Morning Live
Podcasts
Remission in Dermatology: What Does "Clear" Really Mean for Psoriasis and Atopic Dermatitis?
05/19/2026
Joseph F. Merola, MD, MMSc; Alice Bendix Gottlieb, MD, PhD
The bar for treating psoriasis has moved dramatically—from PASI 50 to PASI 75 to complete clearance—and the field is now seriously asking whether remission is an achievable clinical goal, not just an aspirational one.
The bar for treating psoriasis has moved dramatically—from PASI 50 to PASI 75 to complete clearance—and the field is now seriously asking whether remission is an achievable clinical goal, not just an aspirational one.
The bar for treating psoriasis...
05/19/2026
The Dermatologist
News
Oral Icotrokinra Demonstrates High Efficacy and Favorable Safety in Plaque Psoriasis
05/12/2026
Jessica Garlewicz
Investigators analyzed 5 randomized trials including 1951 patients receiving icotrokinra 200 mg once daily or placebo.
Investigators analyzed 5 randomized trials including 1951 patients receiving icotrokinra 200 mg once daily or placebo.
Investigators analyzed 5...
05/12/2026
The Dermatologist
News
Icotrokinra Demonstrates Biologic-Level Efficacy With Oral Administration in Psoriasis
05/12/2026
Jessica Garlewicz
Icotrokinra, an oral interleukin-23 receptor (IL-23R) antagonist, may offer efficacy comparable to biologic therapies in moderate-to-severe plaque psoriasis.
Icotrokinra, an oral interleukin-23 receptor (IL-23R) antagonist, may offer efficacy comparable to biologic therapies in moderate-to-severe plaque psoriasis.
Icotrokinra, an oral...
05/12/2026
The Dermatologist

Popular Articles

psoriasis
News
Shared Biomarkers and Pathways in Psoriasis and Cervical Squamous Cell Carcinoma
06/13/2024
Jessica Garlewicz
Researchers utilized the GSE63514 CESC dataset from the Gene Expression Omnibus and combined 2 psoriasis datasets (GSE13355 and GSE14905) into a single comprehensive dataset after adjusting for batch effects.
Researchers utilized the GSE63514 CESC dataset from the Gene Expression Omnibus and combined 2 psoriasis datasets (GSE13355 and GSE14905) into a single comprehensive dataset after adjusting for batch effects.
Researchers utilized the...
06/13/2024
The Dermatologist
Cover Story
Shared Decision-Making for Older Adult Dermatology Patients
08/05/2024
Jaya Manjunath
This case-based discussion highlights the importance of integrating clinical knowledge with the individualized patient scenario.
This case-based discussion highlights the importance of integrating clinical knowledge with the individualized patient scenario.
This case-based discussion...
08/05/2024
The Dermatologist
acne
News
Targeted Precision Cryotherapy Treatment for Acne Lesions
09/11/2024
Jessica Garlewicz
This pilot clinical trial investigated the feasibility and efficacy of precision cryotherapy as an alternative treatment for acne vulgaris.
This pilot clinical trial investigated the feasibility and efficacy of precision cryotherapy as an alternative treatment for acne vulgaris.
This pilot clinical trial...
09/11/2024
The Dermatologist
AD
FDA Alerts
FDA Approves Tralokinumab Autoinjector for Adults with Moderate-to-Severe Atopic Dermatitis
06/15/2024
Riya Gandhi, MA
The US Food and Drug Administration has approved a new Adbry (tralokinumab-ldrm) 300 mg single-dose autoinjector, offering a new administration option for adult patients with moderate-to-severe atopic dermatitis.
The US Food and Drug Administration has approved a new Adbry (tralokinumab-ldrm) 300 mg single-dose autoinjector, offering a new administration option for adult patients with moderate-to-severe atopic dermatitis.
The US Food and Drug...
06/15/2024
The Dermatologist
AD
Quiz
QUIZ: Psoriasis and Atopic Dermatitis: Nonsteroidal Topical Therapies
09/15/2024
Riya Gandhi, MA
1. According to Dr Linda Stein Gold, how do nonsteroidal topical therapies compare to traditional steroid-based treatments for managing psoriasis and AD?a) They are less effective but safer.b) They are as effective as mid-potency steroids and...
1. According to Dr Linda Stein Gold, how do nonsteroidal topical therapies compare to traditional steroid-based treatments for managing psoriasis and AD?a) They are less effective but safer.b) They are as effective as mid-potency steroids and...
1. According to Dr Linda Stein...
09/15/2024
The Dermatologist
April/May 2026 cover

Current Issue

May 2026
Volume 34
Issue 3
Current Issue
Issue Archive

Latest Quizzes and Trivia

Quiz
Predicting Disease Severity and Persistence in Pediatric Atopic Dermatitis
04/15/2026
Riya Gandhi, MA
Test your expertise in identifying risk factors for persistent pediatric atopic dermatitis and understanding the interplay between barrier dysfunction and immune dysregulation.
Test your expertise in identifying risk factors for persistent pediatric atopic dermatitis and understanding the interplay between barrier dysfunction and immune dysregulation.
Test your expertise in...
04/15/2026
The Dermatologist
Quiz
Type 2 Inflammation and Early Systemic Therapy in Pediatric Atopic Dermatitis
04/05/2026
Riya Gandhi, MA
Assess advanced clinical reasoning in pediatric atopic dermatitis, including implications of type 2 inflammation for diagnosis, treatment timing, and systemic therapy decisions.
Assess advanced clinical reasoning in pediatric atopic dermatitis, including implications of type 2 inflammation for diagnosis, treatment timing, and systemic therapy decisions.
Assess advanced clinical...
04/05/2026
The Dermatologist
Quiz
Disease Heterogeneity in PN
03/15/2026
Riya Gandhi, MA
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
Challenge your understanding of...
03/15/2026
The Dermatologist
Quiz
Rethinking Severity and JAK Inhibitor Strategy in Alopecia Areata
03/12/2026
Riya Gandhi, MA
How should clinicians redefine severe alopecia areata? When is it appropriate to treat ≤20% scalp involvement with oral JAK inhibitors? This expert-level quiz explores remission durability, treatment withdrawal, and practical strategies for...
How should clinicians redefine severe alopecia areata? When is it appropriate to treat ≤20% scalp involvement with oral JAK inhibitors? This expert-level quiz explores remission durability, treatment withdrawal, and practical strategies for...
How should clinicians redefine...
03/12/2026
The Dermatologist
Quiz
Cytokine Hierarchy and Sustained Pruritus in PN
03/10/2026
Riya Gandhi, MA
Explore the hierarchical and cooperative roles of IL-4, IL-13, and IL-31 in sustaining chronic itch and inflammation in prurigo nodularis.
Explore the hierarchical and cooperative roles of IL-4, IL-13, and IL-31 in sustaining chronic itch and inflammation in prurigo nodularis.
Explore the hierarchical and...
03/10/2026
The Dermatologist
Quiz
Type 2 Inflammation as a Pathogenic Driver in Prurigo Nodularis
03/05/2026
Riya Gandhi, MA
Test your understanding of how type 2 immune signaling drives chronic itch in prurigo nodularis through complex neuroimmune interactions.
Test your understanding of how type 2 immune signaling drives chronic itch in prurigo nodularis through complex neuroimmune interactions.
Test your understanding of how...
03/05/2026
The Dermatologist
psoriasis
Quiz
Distinguishing Feature of Generalized Pustular Psoriasis
03/02/2026
Jessica Garlewicz
What is a key distinguishing feature of generalized pustular psoriasis that differentiates it from plaque psoriasis?
What is a key distinguishing feature of generalized pustular psoriasis that differentiates it from plaque psoriasis?
What is a key distinguishing...
03/02/2026
The Dermatologist
psoriasis
Quiz
Quiz: Misdiagnosis of Generalized Pustular Psoriasis
03/02/2026
Jessica Garlewicz
What is the reason generalized pustular psoriasis is often misdiagnosed?
What is the reason generalized pustular psoriasis is often misdiagnosed?
What is the reason generalized...
03/02/2026
The Dermatologist
Quiz
Allergic Disease Progression: Genetics and Environment
02/26/2026
Riya Gandhi, MA
Explore the relationship between allergic disease trends, genetic timelines, and the clinical framework used to describe the progression of atopic conditions across childhood.
Explore the relationship between allergic disease trends, genetic timelines, and the clinical framework used to describe the progression of atopic conditions across childhood.
Explore the relationship between...
02/26/2026
The Dermatologist
Quiz
Early Intervention Strategies in Pediatric Atopic Dermatitis
02/26/2026
Riya Gandhi, MA
Assess your understanding of early skin barrier interventions in infants and the clinical rationale for prompt treatment of atopic dermatitis in young children, including implications for long-term disease outcomes.
Assess your understanding of early skin barrier interventions in infants and the clinical rationale for prompt treatment of atopic dermatitis in young children, including implications for long-term disease outcomes.
Assess your understanding of...
02/26/2026
The Dermatologist

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use